Search
Menu
Home
HTB
2005
January
HTB
January 2005
Contents
Editorial
Volume 6 Number 1 December 2004/January 2005
Treatment alerts
Important new clinical data: potential early virologic failure associated with the combination antiretroviral regimen of tenofovir disoproxil fumarate, didanosine, and either efavirenz or nevirapine in HIV treatment-naive patients with high baseline viral loads
Conference reports
6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV (IWADRLH) 26-28 October 2004, Washington
Nucleoside analogue-related mitochondrial toxicity and link to lipoatrophy: effect of non-thymidine analogues abacavir and tenofovir
Nucleosides reduce PPAR-gamma: a role for rosiglitazone without thymidine analogues?
Potential for uridine to treat mitochondrial toxicity: still only in vitro data
25% patients take Kaletra on an empty stomach: dietary advice often missed at ‘centre of excellence’
rHGH reduces central fat accumulation in adolescent lipodystrophy
Weight loss is associated with elevated PBMC proviral DNA levels
Coronary artery bypass graft is safe in HIV-positive patients but shows higher risk of longer term events
Endothelial dysfunction similar in ARV-experienced and -naive patients
Pravastatin improves lipid profiles but not endothelial function
Indinavir impairs endothelial function without insulin resistance
Treatment interruptions improve lipids within four weeks: IL-2 has no metabolic effect
Improvement of lipids following switch to tenofovir
HCV coinfection linked to discontinuing ART due to toxicity
Restorative treatments for HIV-associated lipoatrophy
44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 30 October-2 November 2004, Washington
Tipranavir in treatment experienced patients: results from RESIST-1
Reverset: first data in patients with nucleoside resistance
Poor response with tenofovir and ddI backbone causes early study termination
Paradoxical CD4 response with tenofovir and ddI backbone
Tenofovir/FTC backbone outperforms AZT/3TC (Combivir) with efavirenz in treatment naive patients; reduced toxicity drives ITT viral efficacy
Limited stability of lopinavir/r (Kaletra) above 25°C
Atorvastatin requires dose reduction with tipranavir/r
Once-daily T-20 is less effective than twice daily: lower potency is related to C trough
Further genetic link to efavirenz absorption
Long-term response to FTC in children is similar to adults
Side effects update: hypersensitivity, heart, bones
Antiretrovirals
Roche discontinue plans for nelfinavir 625mg formulation
Treatment access
Generic ARVs and WHO prequalification list
Cotrimoxazole reduces mortality and morbidity in HIV-positive children: joint WHO/UNAIDS/UNICEF statement
Equitable access for antiretroviral treatment for women
Guidelines
US treatment guidelines updated (Jan 2005)
Updated UK guidelines for HIV and hepatitis coinfection (2005)
Hepatitis coinfection
Interferon plus 3TC for people with HIV/HBV coinfection
On the web
55th Annual Meeting of the American Society for the Study of Liver Diseases (55th AASLD), 29 October – 2 November, 2004, Boston MA
Conference abstracts and reports
Update your WHO/EDM bookshelf
HIV InSite Knowledge Base
Journal articles online at Medscape
Facing up to it: Bio-Alcamid as a facial filler to treat lipoatrophy
PDFs
Volume 6 Number 1 December 2004/January 2005 PDF
HTB RSS
Early access
Lenacapavir submitted to the US FDA with an indication for HIV PrEP
20 December 2024
i-Base guides updated online
5 December 2024
All early access reports
Current issues
December 2024
November 2024
October 2024
Back issues
Special report
Unheard: The medical practice of silencing – by Dr Rageshri Dhairyawan
9 November 2024
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate